Ziccum AB (publ) (ZICC.ST)
SEK 0.25
(0.0%)
SEK 0.25
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.13 Million SEK | 90.07% |
| 2022 | -21.52 Million SEK | -109.51% |
| 2021 | -10.27 Million SEK | 67.51% |
| 2020 | -31.62 Million SEK | -1431.98% |
| 2019 | -2.06 Million SEK | 80.41% |
| 2018 | -10.53 Million SEK | -3662.86% |
| 2017 | -280 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -8.34 Million SEK | -290.5% |
| 2024 Q3 | -678 Thousand SEK | 80.74% |
| 2024 Q2 | -3.52 Million SEK | 57.81% |
| 2023 FY | -2.13 Million SEK | 90.07% |
| 2023 Q1 | -17.73 Million SEK | 17.59% |
| 2023 Q3 | -8.45 Million SEK | 37.13% |
| 2023 Q2 | -13.44 Million SEK | 24.22% |
| 2023 Q4 | -2.13 Million SEK | 74.71% |
| 2022 Q4 | -21.52 Million SEK | 23.19% |
| 2022 Q2 | -34.93 Million SEK | 17.01% |
| 2022 FY | -21.52 Million SEK | -109.51% |
| 2022 Q1 | -42.09 Million SEK | -309.74% |
| 2022 Q3 | -28.02 Million SEK | 19.78% |
| 2021 Q2 | -23.99 Million SEK | 10.48% |
| 2021 FY | -10.27 Million SEK | 67.51% |
| 2021 Q3 | -17.37 Million SEK | 27.57% |
| 2021 Q1 | -26.8 Million SEK | 15.24% |
| 2021 Q4 | -10.27 Million SEK | 40.88% |
| 2020 Q3 | -37.56 Million SEK | 0.44% |
| 2020 Q2 | -37.72 Million SEK | -241.16% |
| 2020 Q1 | -11.05 Million SEK | -435.76% |
| 2020 FY | -31.62 Million SEK | -1431.98% |
| 2020 Q4 | -31.62 Million SEK | 15.82% |
| 2019 Q4 | -2.06 Million SEK | 60.6% |
| 2019 Q3 | -5.23 Million SEK | 24.69% |
| 2019 Q2 | -6.95 Million SEK | 24.39% |
| 2019 FY | -2.06 Million SEK | 80.41% |
| 2019 Q1 | -9.2 Million SEK | 12.67% |
| 2018 FY | -10.53 Million SEK | -3662.86% |
| 2018 Q4 | -10.53 Million SEK | 0.0% |
| 2018 Q1 | 280 Thousand SEK | 200.0% |
| 2018 Q2 | 419 Thousand SEK | 49.64% |
| 2017 Q4 | -280 Thousand SEK | 0.0% |
| 2017 FY | -280 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -2.16 Million SEK | 1.111% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 99.359% |
| NextCell Pharma AB | -46.79 Million SEK | 95.433% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 92.727% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 101.287% |
| AcouSort AB (publ) | -23.98 Million SEK | 91.091% |
| OncoZenge AB (publ) | -12.62 Million SEK | 83.076% |
| Xintela AB (publ) | -7.8 Million SEK | 72.634% |
| Active Biotech AB (publ) | -33.2 Million SEK | 93.563% |
| Alzinova AB (publ) | -21.22 Million SEK | 89.932% |
| Amniotics AB (publ) | -5.63 Million SEK | 62.056% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 95.728% |
| BioArctic AB (publ) | -606.58 Million SEK | 99.648% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 139.574% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.817% |
| Cantargia AB (publ) | -139.74 Million SEK | 98.471% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -131.528% |
| CombiGene AB (publ) | -101.44 Million SEK | 97.893% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 97.397% |
| Genovis AB (publ.) | -43.94 Million SEK | 95.137% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 97.448% |
| Mendus AB (publ) | -96.29 Million SEK | 97.781% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 98.453% |
| Kancera AB (publ) | -45.69 Million SEK | 95.323% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 97.4% |
| LIDDS AB (publ) | -13.51 Million SEK | 84.184% |
| Lipum AB (publ) | -8.46 Million SEK | 74.755% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 93.307% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 104.015% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 88.788% |
| Saniona AB (publ) | 40.44 Million SEK | 105.283% |
| Simris Alg AB (publ) | 85.07 Million SEK | 102.512% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 98.35% |
| Intervacc AB (publ) | -88.16 Million SEK | 97.576% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 95.72% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 110.419% |
| Corline Biomedical AB | -17.01 Million SEK | 87.438% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 97.448% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 94.574% |
| Aptahem AB (publ) | 2.9 Million SEK | 173.471% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 99.351% |
| Fluicell AB (publ) | -2.76 Million SEK | 22.657% |
| Biovica International AB (publ) | -58.73 Million SEK | 96.362% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 95.274% |
| Abliva AB (publ) | -57.24 Million SEK | 96.267% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 98.902% |
| 2cureX AB (publ) | -13.4 Million SEK | 84.056% |
| I-Tech AB | -83.26 Million SEK | 97.433% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 101.586% |
| Cyxone AB (publ) | -16.67 Million SEK | 87.181% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 96.176% |
| Biosergen AB | -1.88 Million SEK | -13.489% |
| Nanologica AB (publ) | -9.38 Million SEK | 77.237% |
| SynAct Pharma AB | -61.75 Million SEK | 96.54% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 90.021% |
| BioInvent International AB (publ) | -236.3 Million SEK | 99.096% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 83.846% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 96.807% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 58.752% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 89.723% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 28.096% |